ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Teprotumumab is on this study

  • The record lists it as a treatment, written “RG1507”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 3:40 AM UTC
  • The role rule says the same.
  • So Teprotumumab's page lists this study under “Testing it”.
17 links0 made here, not in the record34 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT00811993A Study of R1507 inCombination With MultipleStandard ChemotherapyTreatments in Patients WithAdvanced Solid TumorsHoffmann-La RochePhase 1 · terminatedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionDRUGSTeprotumumabEntry “RG1507”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedINT029245Entry “RO1507”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBevacizumabEntry “bevacizumab [Avastin]”, read b…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineEntry “capecitabine [Xeloda]”, read b…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCarboplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCetuximabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundErlotinibEntry “erlotinib [Tarceva]”, read by …›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEtoposideIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGemcitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT010052Entry “mFOLFOX6”, read by our name ru…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSorafenibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTemozolomideIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTrastuzumabEntry “trastuzumab [Herceptin]”, read…›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TeprotumumabClaude Opus 5.5TestedCurrent
Nov 2INT029245Claude Opus 5.5TestedCurrent
Nov 2BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 2CetuximabClaude Opus 5.5BackgroundCurrent
Nov 2DocetaxelClaude Opus 5.5BackgroundCurrent
Nov 2ErlotinibClaude Opus 5.5BackgroundCurrent
Nov 2EtoposideClaude Opus 5.5BackgroundCurrent
Nov 2GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 2IrinotecanClaude Opus 5.5BackgroundCurrent
Nov 2INT010052Claude Opus 5.5BackgroundCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2SorafenibClaude Opus 5.5BackgroundCurrent
Nov 2TemozolomideClaude Opus 5.5BackgroundCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · partnerCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18TeprotumumabRule based · role ruleTestedAgrees
Nov 18INT029245Rule based · role ruleTestedAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18CetuximabRule based · role ruleBackgroundAgrees
Nov 18DocetaxelRule based · role ruleBackgroundAgrees
Nov 18ErlotinibRule based · role ruleBackgroundAgrees
Nov 18EtoposideRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18IrinotecanRule based · role ruleBackgroundAgrees
Nov 18INT010052Rule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18SorafenibRule based · role ruleBackgroundAgrees
Nov 18TemozolomideRule based · role ruleBackgroundAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
As of nowNeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.